88results about How to "Maintain blood levels" patented technology

The invention provides a ticagrelor sustained-release tablet system and a preparation method of the ticagrelor sustained-release tablet system. The preparation method comprises the following steps of: firstly uniformly mixing 10-60% of ticagrelor, 5-60% of a filler and 5-60% of high molecular polymer in percentage by weight, adding a granulating solution to granulate; fully drying the obtained granules at a temperature of 50-60 DEG C, uniformly mixing the sieved granules with 0.25-10% of a lubricant and/or 0-10% of a flow aid, carrying out tabletting to obtain the ticagrelor matrix type sustained-release tablets, wherein the granulating solution is preferably water, an alcohol-water solution or absolute ethyl alcohol; the granule size of the ticagrelor is below 100 micrometers; and the content of the ticagrelor is 50-300mg in the preparation process. The ticagrelor matrix type sustained-release tablet system provided by the invention has the advantages that a patient can take the ticagrelor once a day to ensure that the drug dependence of the patient can be improved and the risk of myocardial infarction or apoplexy caused by acute thrombosis due to a dose of the ticagrelor missing of the patient is reduced.

The invention relates to a novel synthesis method of a CDK4 (cyclin-dependent kinase 4) inhibitor. A reaction of 2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one with acetylchloride is taken as an initial reaction, consequent reactions are performed, and the CDK4 inhibitor is prepared; the preparation method is simple and easy to implement, the yield is high, the quality is high, and industrial production is facilitated.

Pharmaceutical compositions comprising modafinil. The pharmaceutical compositions can have a release profile which is different than that of traditional pharmaceutical compositions of modafinil.

Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time.

The invention discloses a tranexamic acid sustained-release solid composition and a preparation method thereof. The sustained-release solid composition is prepared by taking tranexamic acid as a raw material and adding a sustained-release framework material in a proper proportion. The prepared preparation is capable of achieving zero-order release within 3 h to keep blood concentration steady and is used for treating women suffering from menorrhagia clinically.

The invention discloses a sustained release tablet containing a donepezil hydrochloride serving as an active component. The sustained release tablet provided by the invention comprises the donepezil hydrochloride serving as an active component, a sustained-release material and other auxiliary materials, wherein the weight ratio of the donepezil hydrochloride serving as an active component to the sustained-release material is 1:(0.2-20), preferably 1:(0.5-10) and further preferably 1:(0.7-8). The sustained release tablet containing donepezil hydrochloride prepared by the invention is released steadily, which is favorable for the reduction of the fluctuation of the in-vivo medicament, thus the side effect is reduced, and the sustained release tablet is more suitable for treating patients suffering from Alzheimer-type dementia.

The invention discloses double-controlled release gliclazide sustained-release capsules and a preparation method thereof. Contents filled into the sustained-release capsules are gliclazide sustained-release pellets of which surfaces are coated with quick release film coatings. Based on 1,000 capsules, the gliclazide sustained-release pellets are prepared from the following raw materials by weight: 20 to 30 grams of gliclazide, 30 to 50 grams of microcrystalline cellulose, 40 to 60 grams of lactose, 2 to 8 grams of hydroxypropyl methylcellulose 4000cp and 30 to 60 grams of water; and the quickrelease film coatings are prepared from the following raw materials by weight: 5 to 20 grams of gliclazide, 10 to 40 grams of EudragitRL100, 5 to 30 grams of talcpowder and 300 grams of ethanol at the volume concentration of 95 percent. Compared with the prior art, the capsules provided by the invention can develop the advantages of multi-unit preparations at the same time of meeting requirementson the quick response of medicaments and keeping a certain blood concentration; and the preparation method for the capsules is simple and easy to control.

The invention discloses a decoction-free extraction process for precious Chinese herbal medicines. The process includes the steps: 1) cleaning, drying and grinding the Chinese herbal medicines into 20-30-mesh particles; 2) adopting a supercritical CO2 extraction process for removing heavy metals from the Chinese herbal medicine particles obtained at the step 1); 3) roasting the Chinese herbal medicine particles with the heavy metals removed at the step 2) for 50-60min at the temperature of 45-50 DEG C until the water content is 0.3-0.5wt%; 4) subjecting the Chinese herbal medicine particles roasted at the step 3) to ultrafine pulverization until the particle size is 0.35-0.75micrometer; 5) performing wall-breaking treatment, namely adding auxiliary materials into the Chinese herbal medicine particles obtained at the step 4), and extracting active ingredients by application of a low-temperature micro-nano wall-breaking technique. By effective rejection of heavy metal pollution, pharmacological functions of the Chinese herbal medicines can be improved, and side effects are reduced; by application of the cell wall breaking technique for powder processing, biological activity and bioavailability of the Chinese herbal medicines can be improved.

The invention discloses a cholesterol hydrophobic modification pullulan-donepezil-polysorbate 80 nano particle. The nano particle comprises a cholesterol hydrophobic modification pullulan nano particle, donepezil loaded in the cholesterol hydrophobic modification pullulan nano particle and polysorbate 80 adsorbed on the surface of the cholesterol hydrophobic modification pullulan nano particle. The cholesterol hydrophobic modification pullulan-donepezil-polysorbate 80 nano particle has good drug loading capacity, encapsulation efficiency and slow-release effect on the donepezil, and can be used for maintaining blood concentration within a longer time, prolonging medicine taking intervals and improving patient compliance. In addition, as the stability is improved, the dosage, which enters the whole body to circulate, is reduced, more nano particles stride a blood brain barrier before releasing medicine, so that the medicine is enriched at the brain, the release after location is realized, not only is the dosage reduced, but also the toxicity to a peripheral nervous system is reduced.

A pharmaceutical composition for transdermal administration comprising perospirone of the formula (1):

or a pharmaceutically acceptable acid addition salt thereof, which can inhibit the generation of metabolites and continuously maintain the blood level of perospirone.

The invention relates to a compound sustained-release preparation and a preparation method thereof, and the compound sustained-release preparation comprises Epristeride, terazosin hydrochloride and pharmaceutically acceptable auxiliary materials, wherein the Epristeride and the terazosin hydrochloride are used as the active components, the Epristeride is prepared into a sustained-release part, and the terazosin hydrochloride is prepared into an ordinary-release part, so that the two medicines are kept in an effective blood concentration range in vivo, the adverse effect of the medicines and the administration frequency are reduced, and the safety and effectiveness of pharmacy and the compliance of patients are improved.

The invention relates to a gamithromycin emulsion. Each 100g of the gamithromycin emulsion comprises the following components by weight of 0.01 to 5.0 g of gamithromycin, 0.1 to 16.0 g of lysimachia christinae hance oil, 0.1 to 5.0 g of ethyl linoleate, 8.0 to 30.0 g of sucrose fatty acid ester, 10.0 to 20.0 g of polyoxyethylene ether (60) hydrogenated castor oil, 5.0 to 10.0 g of 1, 2-propylene glycol and the balance of deionized water. Meanwhile, the invention further discloses a preparation method, the process operability is high, and production conversion is facilitated. The emulsion disclosed by the invention is in an oil-water mutual wrapping type, the prepared product can be infinitely diluted with water and can also be infinitely diluted with oil, after being diluted with water, the emulsion can meet the drinking water administration requirement and is convenient to use, and after being diluted with oil, the emulsion can be prepared into a slow-release emulsion, so that a long-acting antibacterial effect is achieved, and the administration frequency is reduced. The emulsion disclosed by the invention can be used for preventing and treating ileitis diseases caused by pig Lawsonia intracellularis infection, has an effect obviously better than that of the prior art, and has a wide market application prospect.

The technical problem solved by the invention is to provide an oral sustained-release tablet of quetiapine and its salts which can effectively and continuously release for more than 12 hours, is slow in medical effect release, can stably maintain the effective plasma concentration for 24 hours, is long in release period, less in toxic or side effect, and convenient for administration; the main components are quetiapine with active components, a skeletal material with sustained-release effect, and an excipient; the invention is characterized in that on a basis of the total weight of the tablet, the tablet comprises 5%-50% of quetiapine with active components, 5%-50% of skeletal material with sustained-release effect, and 20%-50% of excipients. Polyoxyethylene with one or several different models is selected as the skeletal material. The excipient comprises a proper amount of sodium citrate dihydrate compounds. Polyoxyethylene is selected which can prolong the sustained-release period; the release period is greatly increased; the medicinal effect is released stably and slowly; the plasma concentration is guaranteed; the disease condition is controlled stably; patients are provided with 24-hour effective treatment; and the invention is widely applicable to single-dosage quetiapine treatment.

The invention provides an irinotecan hydrochloride lipidosome composition, which consists of the following ingredients in parts by weight: 1 part of irinotecan hydrochloride, 2-6 parts of hydrogenated soybean phosphatide, 1.0-2.25 -parts of cholesterol and 0.04-0.20 parts of distearoyl phosphoethanolamine-polyethylene glycol 2000. The invention also provides a preparation method of the lipidosome composition. The lipidosome disclosed by the invention significantly reduces cost, and the lipidosome is good in stability,low in content of impurities, high in safety and easy for industrial mass production.

The invention discloses an irbesartan hydrochlorothiazide capsule. The capsule includes the components of irbesartan, hydrochlorothiazide, carrageenan, mannitol, crosslinked polyvinylpyrrolidone and talcum powder. The irbesartan hydrochlorothiazide capsule enables medicines to slowly release step by step, the phenomenon of sudden releasing cannot occur, blood concentration is stable, medicine effect can maintain more than 8 hours, adverse reaction caused by medicine sudden releasing is avoided, and pharmacy safety is added. The irbesartan hydrochlorothiazide capsule can be used for treating primary hypertension.

The invention discloses a new type sustained release tablets of tramadol hydrochloride and the preparation method. The sustained release tablets comprise tablet core and membrane clothing sheet. The tablet core contains sustained release capsule of tramadol hydrochloride with its weight being 80-90% of total weight of tablet core, and the sustained release capsule is prepared with tramadol hydrochloride and sustained release material with ratio being 1: 1.2-1.5. The sustained release capsule also contains 10% monoglyceride. The sustained release tablet is characterized by stable effective blood concentration, increased biological utilization rate, reduced side effect, good taste and small intake amount of one time per day.

An injection of aniracetam for intravenous injection is prepared from aniracetam, dissolved by propylene glycol solvent, the mixture of alcohol and water for injection, anti-oxidizing agent and pH regulator.

The invention discloses a radix ophiopogonis oligosaccharide slow-release tablet and a preparation method thereof. The radix ophiopogonis oligosaccharide slow-release tablet is prepared from the following raw materials in parts by mass: 1 part of active ingredient of radix ophiopogonis, 0.5 to 1.5 parts of slow-release framework material, 0.3 to 0.6 part of filling agent, and 0.01 to 0.02 part of lubricant, wherein the slow-release framework material preferably selects hydroxypropyl methyl cellulose, sodium carboxymethylcellulose or carboxyethyl cellulose; the filling agent comprises microcrystalline cellulose, lactose or starch; the lubricant comprises magnesium stearate, superfine silica powder or talcum powder. Compared with the prior art, the radix ophiopogonis oligosaccharide slow-release tablet has the advantages that after taking, the radix ophiopogonis oligosaccharide can be effectively and stably released in a human body, so that the effective plasma concentration and time can be maintained, and the peak and valley of plasma concentration can be avoided; under the premises of ensuring therapy effect, the side effect caused by overhigh plasma concentration can be avoided; the preparation technology is simple, and the radix ophiopogonis oligosaccharide slow-release tablet is suitable for industrial production.

The invention relates to a method for treating CNS diseases and provides lamotrigine orally disintegrating sustained release tablets which can be rapidly disintegrated in the oral cavity and can reflect very similar release rate unrelated to the pH value of the environment in the whole gastrointestinal tract. The preparation comprises lamotrigine, organic acids, a disintegrating agent, a polymer controlling release and an enteric polymer. The compositions can be used for treating epilepsy and bipolar disorder, particularly patients suffering from dysphagia and improving the compliance of patients suffering from the bipolar disorder. The orally disintegrating tablets are prepared according to the method disclosed by the invention, the release rate of active ingredients can be controlled, and the bioequivalence and clinical safety and effectiveness of the product are guaranteed.